Outlook of IL-6 signaling blockade for COVID-19 pneumonia
Abstract In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of new treatment for COVID-19 pneumonia. Given physiological roles of IL-6 in inflammatory conditions and the data from real world, IL-6 signal inhibitors, along with standard of care (SOC) treatment, might provide efficacy, offering the potential to treat COVID-19 in hospitalized populations more effectively than current SOC alone. Therefore, on-going and planned randomized placebo-controlled studies in combination with SOC and other therapeutics to assess safety and efficacy of IL-6 signal inhibitors in hospitalized patients with severe COVID-19 pneumonia will be warranted to address the high unmet need and burden of disease in this severely ill population..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
Inflammation and Regeneration - 40(2020), 1, Seite 8 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Misato Hashizume [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
COVID-19 pneumonia |
---|
doi: |
10.1186/s41232-020-00134-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ076127818 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ076127818 | ||
003 | DE-627 | ||
005 | 20230309141726.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s41232-020-00134-7 |2 doi | |
035 | |a (DE-627)DOAJ076127818 | ||
035 | |a (DE-599)DOAJ129ea98e3e404292a4584dcde5db4e94 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RB1-214 | |
100 | 0 | |a Misato Hashizume |e verfasserin |4 aut | |
245 | 1 | 0 | |a Outlook of IL-6 signaling blockade for COVID-19 pneumonia |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of new treatment for COVID-19 pneumonia. Given physiological roles of IL-6 in inflammatory conditions and the data from real world, IL-6 signal inhibitors, along with standard of care (SOC) treatment, might provide efficacy, offering the potential to treat COVID-19 in hospitalized populations more effectively than current SOC alone. Therefore, on-going and planned randomized placebo-controlled studies in combination with SOC and other therapeutics to assess safety and efficacy of IL-6 signal inhibitors in hospitalized patients with severe COVID-19 pneumonia will be warranted to address the high unmet need and burden of disease in this severely ill population. | ||
650 | 4 | |a Interleukin-6 | |
650 | 4 | |a COVID-19 pneumonia | |
650 | 4 | |a Cytokine release syndrome | |
650 | 4 | |a Tocilizumab | |
650 | 4 | |a Sarilumab | |
650 | 4 | |a Siltuximab | |
653 | 0 | |a Pathology | |
773 | 0 | 8 | |i In |t Inflammation and Regeneration |d BMC, 2016 |g 40(2020), 1, Seite 8 |w (DE-627)DOAJ00013371X |x 18808190 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:2020 |g number:1 |g pages:8 |
856 | 4 | 0 | |u https://doi.org/10.1186/s41232-020-00134-7 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/129ea98e3e404292a4584dcde5db4e94 |z kostenfrei |
856 | 4 | 0 | |u http://link.springer.com/article/10.1186/s41232-020-00134-7 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1880-8190 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 40 |j 2020 |e 1 |h 8 |